SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

SPY is trending due to futures surging on news of a potential ceasefire in the Middle East and cooling oil prices, driving active community debate between bears expecting a bull trap and bulls celebrating the reversal. Traders are heavily focused on navigating extreme volatility ahead of a packed week featuring major big tech earnings and central bank updates.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

Rigetti Computing is trending as investors react to new federal executive orders aimed at accelerating U.S. quantum technology leadership and secure data migration. The community is actively debating the stock's long-term potential versus concerns over high cash burn rates, recent insider selling, and the reliability of government-linked catalysts.

Omeros Corp. operates as a biopharmaceutical company, which engages in the research, discovery, development, and commercialization of small-molecule and protein therapeutics targeting immunologic diseases. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corp is trending as investors react to a negative CHMP opinion for Yartemlea in Europe, fueling volatility while the company prepares for an appeal and re-examination. The community is actively debating the impact of this regulatory setback against the backdrop of US-based commercial momentum, recent insider debt repurchases, and the upcoming activation of a permanent J-code for reimbursement.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IonQ is facing significant downward pressure as investors rotate out of high-valuation quantum stocks, leading to heavy short-selling activity and bearish sentiment regarding current entry points. Despite the short-term volatility, the community remains divided, with long-term investors pointing to IonQ's trapped-ion technical leadership and government partnerships as fundamental catalysts for eventual recovery.

Venture Global, Inc. engages in the provision of United States liquefied natural gas sourced from resource rich North American natural gas basins. It operates through the following segments: Calcasieu Project, Plaquemines Project, CP2 Project, and Sales and shipping. The company was founded by Michael Sabel and Robert Pender in 2023 and is headquartered in Arlington, VA.

Venture Global Inc. - Ordinary Shares - Class A

Venture Global Inc

Venture Global is surging as investors react to a significant jump in liquefaction fees and strong Q2 earnings that underscore the company's ability to capitalize on the elevated global LNG spot prices resulting from ongoing Middle East shipping disruptions. The community is focused on the stock's role as a critical energy infrastructure provider, with bullish sentiment fueled by supply constraints in the Strait of Hormuz and anticipation for capacity expansion projects coming online.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is facing a pivotal week as investors await the upcoming FDA Advisory Committee meeting to review the clinical data for its Duchenne muscular dystrophy treatment, Deramiocel. The community is focused on the potential for a dual-label approval and the implications of a high short interest, with many anticipating significant volatility following the release of the briefing documents.

SK hynix, Inc. engages in the manufacture and sale of semiconductor products. Its products include dynamic random access memory, flash memory, complementary metal oxide semiconductor image sensor, and others. The company was founded on October 15, 1949 and is headquartered in Icheon, South Korea.

SK Hynix Inc - ADR

SK Hynix is experiencing significant volatility and trading volume as investors react to a massive 500 billion dollar AI partnership with Nvidia, even as community sentiment remains divided over the sustainability of its current price and the ADR's premium relative to its Korea-listed shares. Market participants are intensely focused on upcoming earnings and the potential for shifts in global AI infrastructure capital expenditure to sustain the semiconductor demand cycle.

Amkor Technology, Inc. engages in the provision of outsourced semiconductor packaging and test services. Its services include design, package characterization, test, and wafer bumping services. The company was founded in 1968 and is headquartered in Tempe, AZ.

AMKOR Technology Inc.

AMKR is attracting significant investor attention as a key player in the semiconductor advanced packaging supply chain, with community sentiment fueled by its strategic partnerships with major AI chip designers like NVIDIA, AMD, and TSMC. Traders are closely monitoring the upcoming earnings season for confirmation of the company's growth trajectory and its ability to capitalize on the ongoing demand for high-performance AI infrastructure.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: QNX, Secure Communications, and Licensing. The QNX segment includes development of safe and reliable software for embedded systems across technology-driven industries. The Secure Communications segment delivers operational resiliency with a government-grade portfolio of secure, certified solutions for mobile fortification, critical communications and crisis management. The Licensing segment focuses on management and monetization of the firm's global patent portfolio. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is trending as investors focus on the expansion of its QNX software platform into the high-growth fields of physical AI, robotics, and next-generation software-defined vehicles. The community remains highly bullish on the company's long-term potential, actively discussing the imminent release of the 'Alloy Kore' platform and the broader strategic value of its safety-certified foundational technology amid industry partnerships with major chipmakers and automotive OEMs.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid Group is experiencing extreme volatility driven by a short squeeze, fueled by community-led buying, high borrow fees, and a aggressive rebuttal from leadership regarding bankruptcy rumors. Investors are intensely focused on short interest dynamics and potential partnership catalysts as the stock tests key technical levels amid broader EV sector pressure.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

4D Molecular's One-Shot Eye Therapy Delivers Two-Year Win

4D Molecular Therapeutics reports positive 2-year Phase 2b data for 4D-150 in wet AMD, showing up to an 87% cut in treatment burden.read more...

Strength Seen in 4D Molecular Therapeutics (FDMT): Can Its 7.9% Jump Turn into More Strength?

4D Molecular Therapeutics (FDMT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

4D Molecular Therapeutics Inc (FDMT): Gene Therapy Stock Made for You?

4D Molecular Therapeutics Inc (FDMT): Gene Therapy Stock Made for You...

4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates

4D Molecular Therapeutics (FDMT) delivered earnings and revenue surprises of -4.12% and -19.07%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Aclaris Therapeutics (ACRS) Reports Q1 Loss, Beats Revenue Estimates

Aclaris (ACRS) delivered earnings and revenue surprises of +7.24% and +46.12%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Consensus Recommendation of "Moderate Buy" from Analysts

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) has been given an average recommendation of "Moderate Buy" by the ten research firms that are covering the stock, Marketbeat.com...

electroCore (ECOR) Moves 7.1% Higher: Will This Strength Last?

electroCore (ECOR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

4D Molecular Therapeutics, Inc. $FDMT Shares Sold by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. decreased its position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) by 55.4% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 296,199 shares of the company's stock after...

4D Molecular Therapeutics' (FDMT) "Buy" Rating Reaffirmed at Jefferies Financial Group

Jefferies Financial Group reiterated a "buy" rating and issued a $21.00 target price (down from $40.00) on shares of 4D Molecular Therapeutics in a research report on Monday...

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Given Consensus Recommendation of "Moderate Buy" by Brokerages

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) has earned an average rating of "Moderate Buy" from the nine ratings firms that are presently covering the firm, Marketbeat Ratings...

4DMT operates as a clinical-stage genetic medicines company focused on inventing and developing genetic medicines to treat large market diseases in ophthalmology, pulmonology and cardiology. It develops genetic medicines using its proprietary invention platform, Therapeutic Vector Evolution. It combines the power of the Nobel Prize-winning technology, directed evolution, with approximately one billion synthetic AAV capsid-derived sequences. Its product design, development and manufacturing engine create a valuable and diverse product pipeline. The company is currently advancing five clinical-stage and two preclinical product candidates, each tailored to address rare and large market diseases. 4DMT was founded by David H. Kirn, Melissa Kotterman, Theresa Janke, and David Schaffer on September 12, 2013 and is headquartered in Emeryville, CA.

4D Molecular Therapeutics Inc

FDMT Stock Gains Pre-Market After Positive Study Data For Experimental Drug In Eye Disease

Equity

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$10.07
Prev Close	$10.38
Open	$10.38
Dividend Yield	0.00%
50-Day Moving Average	$10.39
Beta	1.42
Avg. Volume	1.12M
PE Ratio	-3.78

52-Week High	$14.00
52-Week Low	$4.27
Market Capitalization	$526.42M
EPS (Annual)	-$2.42
Price to Book	1.17
Revenue Per Employee	$434,739.80

Feed

News

Sentiment

Earnings

Fundamentals

Info

FDMT4D Molecular Therapeutics Inc

Latest FDMT News